2578 related articles for article (PubMed ID: 18590786)
1. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
2. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
[TBL] [Abstract][Full Text] [Related]
3. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum.
Healer J; Murphy V; Hodder AN; Masciantonio R; Gemmill AW; Anders RF; Cowman AF; Batchelor A
Mol Microbiol; 2004 Apr; 52(1):159-68. PubMed ID: 15049818
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
6. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
[TBL] [Abstract][Full Text] [Related]
7. [Protective antibody response to recombinant fragments of Plasmodium falciparum apical membrane antigen 1].
Li X; Xue CF; Liu ZX; Wang XF; Ding J; Lei JC; Zhen RF
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2003; 21(2):80-3. PubMed ID: 12884614
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
Teo WH; Nurul AA; Norazmi MN
Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE
Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706
[TBL] [Abstract][Full Text] [Related]
10. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism in msp-2, ama-1 and csp genes in Plasmodium falciparum field isolates from north and north-western India.
Farooq U; Malla N; Dubey ML
J Vector Borne Dis; 2009 Jun; 46(2):109-16. PubMed ID: 19502690
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
13. Genetic diversity and natural selection at the domain I of apical membrane antigen-1 (AMA-1) of Plasmodium falciparum in isolates from Iran.
Mardani A; Keshavarz H; Heidari A; Hajjaran H; Raeisi A; Khorramizadeh MR
Exp Parasitol; 2012 Apr; 130(4):456-62. PubMed ID: 22306282
[TBL] [Abstract][Full Text] [Related]
14. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
15. Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1.
Cortés A; Mellombo M; Masciantonio R; Murphy VJ; Reeder JC; Anders RF
Infect Immun; 2005 Jan; 73(1):422-30. PubMed ID: 15618180
[TBL] [Abstract][Full Text] [Related]
16. Plasmodium falciparum: genetic polymorphism in apical membrane antigen-1 gene from Indian isolates.
Rajesh V; Singamsetti VK; Vidya S; Gowrishankar M; Elamaran M; Tripathi J; Radhika NB; Kochar D; Ranjan A; Roy SK; Das A
Exp Parasitol; 2008 May; 119(1):144-51. PubMed ID: 18343371
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.
Moorthy SA; Yasawardena SG; Ramasamy R
Vaccine; 2009 Aug; 27(36):4947-52. PubMed ID: 19545652
[TBL] [Abstract][Full Text] [Related]
20. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
Chang SP; Nikaido CM; Hashimoto AC; Hashiro CQ; Yokota BT; Hui GS
J Immunol; 1994 Apr; 152(7):3483-90. PubMed ID: 8144929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
